Changing the name of diabetes insipidus : a position statement of The Working Group for Renaming Diabetes Insipidus

[Abstract. ] "What's in a name? That which we call a rose/By any other name would smell as sweet." (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic mea...

Full description

Saved in:
Bibliographic Details
Published inENDOCRINE JOURNAL Vol. 69; no. 11; pp. 1281 - 1284
Main Authors The Working Group for Renaming Diabetes Insipidus, Hiroshi Arima, Timothy Cheetham, Mirjam Christ-Crain, Deborah Cooper, Mark Gurnell, Juliana B Drummond, Miles Levy, Ann I McCormack, Joseph Verbalis, John Newell-Price, John A H Wass
Format Journal Article
LanguageEnglish
Japanese
Published The Japan Endocrine Society 14.10.2022
Online AccessGet full text

Cover

More Information
Summary:[Abstract. ] "What's in a name? That which we call a rose/By any other name would smell as sweet." (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and pediatric endocrine societies now proposes changing the name of "diabetes insipidus" to "Arginine Vasopressin Deficiency (AVP-D)" for central etiologies, and "Arginine Vasopressin Resistance (AVP-R)" for nephrogenic etiologies. This editorial provides both the historical context and the rational for this proposed name change.
ISSN:0918-8959
DOI:10.1210/clinem/dgac547